BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 21549228)

  • 21. Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes.
    Egger ME; Bhutiani N; Farmer RW; Stromberg AJ; Martin RC; Quillo AR; McMasters KM; Scoggins CR
    Surgery; 2016 May; 159(5):1412-21. PubMed ID: 26775577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study.
    Harlow SP; Krag DN; Ashikaga T; Weaver DL; Meijer SJ; Loggie BW; Tanabe KK; Whitworth P; Kuhn J; Kusminsky R; Carp NZ; Gadd M; Rawlings M; Slingluff CL
    Melanoma Res; 2001 Feb; 11(1):45-55. PubMed ID: 11254115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value of DNA ploidy and S-phase fraction as prognostic factors in stage III cutaneous melanoma.
    Martin G; Halwani F; Shibata H; Meterissian S
    Can J Surg; 2000 Feb; 43(1):29-34. PubMed ID: 10714254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beta 1 integrin expression in malignant melanoma predicts occult lymph node metastases.
    Hieken TJ; Ronan SG; Farolan M; Shilkaitis AL; Kim DK; Das Gupta TK
    Surgery; 1995 Oct; 118(4):669-73; discussion 673-5. PubMed ID: 7570321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors predicting recurrence and survival in sentinel lymph node-positive melanoma patients.
    Murali R; Desilva C; Thompson JF; Scolyer RA
    Ann Surg; 2011 Jun; 253(6):1155-64. PubMed ID: 21412144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S100 protein serum levels in cutaneous malignant melanoma.
    Seregni E; Massaron S; Martinetti A; Illeni MT; Rovini D; Belli F; Agresti R; Greco M; Cascinelli N; Bombardieri E
    Oncol Rep; 1998; 5(3):601-4. PubMed ID: 9538159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased Angiogenesis and Lymphangiogenesis in Metastatic Sentinel Lymph Nodes Is Associated With Nonsentinel Lymph Node Involvement and Distant Metastasis in Patients With Melanoma.
    Pastushenko I; Van den Eynden GG; Vicente-Arregui S; Prieto-Torres L; Alvarez-Alegret R; Querol I; Dirix LY; Carapeto FJ; Vermeulen PB; Van Laere SJ
    Am J Dermatopathol; 2016 May; 38(5):338-46. PubMed ID: 26909582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular staging of malignant melanoma: correlation with clinical outcome.
    Shivers SC; Wang X; Li W; Joseph E; Messina J; Glass LF; DeConti R; Cruse CW; Berman C; Fenske NA; Lyman GH; Reintgen DS
    JAMA; 1998 Oct; 280(16):1410-5. PubMed ID: 9801000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Common prognostic factors for stage III melanoma patients and for stage I and II melanoma patients with recurrence to their regional lymph nodes.
    Konstadoulakis MM; Messaris E; Zografos G; Ricaniadis N; Androulakis G; Karakousis C
    Melanoma Res; 2002 Aug; 12(4):357-64. PubMed ID: 12170185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors predicting survival in thick melanoma: Do all thick melanomas have the same prognosis?
    Han D; Han G; Morrison S; Leong SP; Kashani-Sabet M; Vetto J; White R; Schneebaum S; Pockaj B; Mozzillo N; Sondak VK; Zager JS
    Surgery; 2020 Sep; 168(3):518-526. PubMed ID: 32669204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prognosis of malignant melanoma following dissection regional lymph node metastases].
    Sprakel B; Stenschke F; Unnewehr M; Ladas A; Senninger N
    Chirurg; 2003 Jan; 74(1):55-60. PubMed ID: 12552406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of sentinel lymph node biopsy in patients with local recurrence or in-transit metastasis of melanoma.
    Gipponi M; Solari N; Giovinazzo D; Queirolo P; Bertoglio S; Villa G; Gualco M; Bleidl D; Cafiero F
    Anticancer Res; 2014 Jun; 34(6):3197-203. PubMed ID: 24922694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgical management of tumor-positive interval node in melanoma patients: An observational study.
    Nacchiero E; Vestita M; Robusto F; Maruccia M; Annoscia P; Giudice G
    Medicine (Baltimore); 2018 May; 97(18):e0584. PubMed ID: 29718857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of melanoma cells in the lymphatic drainage after lymph node dissection in melanoma patients by using two-marker reverse transcriptase-polymerase chain reaction assay.
    Włodzimierz R; Rutkowski P; Nowecki ZI; Kulik J; Nasierowska-Guttmejer A; Siedlecki JA
    Ann Surg Oncol; 2004 Nov; 11(11):988-97. PubMed ID: 15525828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.
    Burmeister BH; Henderson MA; Ainslie J; Fisher R; Di Iulio J; Smithers BM; Hong A; Shannon K; Scolyer RA; Carruthers S; Coventry BJ; Babington S; Duprat J; Hoekstra HJ; Thompson JF
    Lancet Oncol; 2012 Jun; 13(6):589-97. PubMed ID: 22575589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sentinel node tumor burden in prediction of prognosis in melanoma patients.
    Palve J; Ylitalo L; Luukkaala T; Jernman J; Korhonen N
    Clin Exp Metastasis; 2020 Apr; 37(2):365-376. PubMed ID: 32076905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic importance of lymph node tumor burden in melanoma patients staged by sentinel node biopsy.
    Ranieri JM; Wagner JD; Azuaje R; Davidson D; Wenck S; Fyffe J; Coleman JJ
    Ann Surg Oncol; 2002 Dec; 9(10):975-81. PubMed ID: 12464589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma.
    Gershenwald JE; Colome MI; Lee JE; Mansfield PF; Tseng C; Lee JJ; Balch CM; Ross MI
    J Clin Oncol; 1998 Jun; 16(6):2253-60. PubMed ID: 9626228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of routine ilioinguinal lymph node dissection for palpable inguinal melanoma nodal metastasis.
    Glover AR; Allan CP; Wilkinson MJ; Strauss DC; Thomas JM; Hayes AJ
    Br J Surg; 2014 Jun; 101(7):811-9. PubMed ID: 24752717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients.
    Mian S; Ugurel S; Parkinson E; Schlenzka I; Dryden I; Lancashire L; Ball G; Creaser C; Rees R; Schadendorf D
    J Clin Oncol; 2005 Aug; 23(22):5088-93. PubMed ID: 16051955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.